Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06503237 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 2024 to Mar 2026
    • Start date: Sep 26, 2023 to Nov 9, 2023
    • Secondary endpoints: details revised at 1 of 5 entries
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory rheumatoid arthritis. This study aims to evaluate the safety and efficacy of the treatment with Anti-CD19 CART.
Trial Details
NCT Number NCT06503237
Lead Sponsor The First Affiliated Hospital of University of Science and Technology of China
Conditions
(from sponsor)		 Rheumatoid Arthritis
Related terms Arthritis, Rheumatoid
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov